Pharmaceutical composition
A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition.
1. A method for maintaining a therapeutically effective concentration of testosterone in the blood serum of a male for treating hypogonadism which comprises transdermally delivering to the male by applying to the skin a composition which is in the form of a topical gel, which has a viscosity of about 500 to about 20,000 cps and a pH of about 3 to about 9, and comprises: (A) about 0.1 to about 5 wt. % of testosterone; (B) about 0.5 to about 25 wt. % of a Hsieh enhancer; (C) about 0.1 to about 10 wt. % of a thickening agent; and (D) a mixture of solvents which include about 40 to about 80 wt. % of lower alkanol; wherein the Hsieh enhancer is selected from the group consisting of 3-methylcyclopentadecanone, 9-cycloheptadecen-1-one, cyclohexadecanone, cyclopentadecanone and oxacyclohexadecan-2-one.
2. The method according to claim 1 in which testosterone is delivered transdermally to the blood of a male patient by use of the composition in the form of a unit dose such that, following a single application of the unit dose to the patient, the amount of circulating testosterone (AUC 0-24 ) in the blood serum of the patient achieved in the 24-hour period following the application is about 100 to about 35,000 ng·h/dL greater than the amount of circulating testosterone (AUC 0-24 ) in the blood serum of the patient that would have been achieved in the same 24-hour period had the dose not been administered.
3. The method of claim 1 , wherein the composition further comprises a crystallization inhibitor.
4. The method of claim 3 , wherein the crystallization inhibitor is polyethylene glycol.
5. The method of claim 4 , wherein the polyethylene glycol is present in an amount ranging from about 0.001 to about 5 wt. %.
6. The method of claim 1 , wherein the composition has a viscosity ranging from about 1,000 to about 9,000 cps.
7. The method of claim 1 , wherein the composition has a pH ranging from about 4 to about 8.
8. The method of claim 1 , wherein the mixture of solvents comprises a co-solvent selected from the group consisting of glycerin, propylene glycol, polyethylene, polypropylene, silicone and mixtures thereof.
9. The method of claim 8 , wherein the co-solvent comprises glycerin.
10. The method of claim 8 , wherein the co-solvent comprises propylene glycol.